- Home
- INCY vs DOCS Comparison
INCY vs DOCS Comparison
Compare INCY & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- DOCS
- Stock Information
- Founded
- INCY 1991
- DOCS 2010
- Country
- INCY United States
- DOCS United States
- Employees
- INCY N/A
- DOCS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- DOCS Retail: Computer Software & Peripheral Equipment
- Sector
- INCY Health Care
- DOCS Technology
- Exchange
- INCY Nasdaq
- DOCS Nasdaq
- Market Cap
- INCY 13.0B
- DOCS 10.9B
- IPO Year
- INCY 1993
- DOCS 2021
- Fundamental
- Price
- INCY $86.64
- DOCS $69.35
- Analyst Decision
- INCY Buy
- DOCS Buy
- Analyst Count
- INCY 20
- DOCS 19
- Target Price
- INCY $80.31
- DOCS $66.74
- AVG Volume (30 Days)
- INCY 1.7M
- DOCS 1.5M
- Earning Date
- INCY 10-28-2025
- DOCS 08-07-2025
- Dividend Yield
- INCY N/A
- DOCS N/A
- EPS Growth
- INCY 900.04
- DOCS 45.79
- EPS
- INCY 4.37
- DOCS 1.17
- Revenue
- INCY $4,584,996,000.00
- DOCS $589,636,000.00
- Revenue This Year
- INCY $16.26
- DOCS $13.33
- Revenue Next Year
- INCY $11.07
- DOCS $10.90
- P/E Ratio
- INCY $19.84
- DOCS $59.25
- Revenue Growth
- INCY 18.87
- DOCS 19.45
- 52 Week Low
- INCY $53.56
- DOCS $35.32
- 52 Week High
- INCY $87.99
- DOCS $85.21
- Technical
- Relative Strength Index (RSI)
- INCY 64.89
- DOCS 64.63
- Support Level
- INCY $83.41
- DOCS $65.33
- Resistance Level
- INCY $87.99
- DOCS $69.80
- Average True Range (ATR)
- INCY 1.68
- DOCS 1.89
- MACD
- INCY -0.37
- DOCS 0.17
- Stochastic Oscillator
- INCY 70.52
- DOCS 94.11
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.